This is a multicenter, retrospective clinical study, in patients with brucellosis, to analyze the clinical characteristics, complications, and the impact of different treatment options on long-term prognosis of patients with brucellosis. All hospitalized patients diagnosed with brucellosis between 2016 and 2021 were included from the electronic medical record systems of eight centers, collecting demographics, hospitalization information, clinical information, laboratories, imaging studies, treatment regimens, and disease outcome and other information.

Inclusion Criteria:

• Age and gender are not limited;

• Discharged patients diagnosed with brucellosis

• Specific reference to the People's Republic of China's health industry standard "Diagnosis for brucellosis" (WS269-2019) diagnosed as a patient with brucellosis, that is, the patient meets a suspected or clinically diagnosed case and passes the confirmatory test mentioned below at the same time Either to prove:

  1. Brucella is isolated from any pathological material culture such as blood, bone marrow, other body fluids and excreta of patients.
  2. The test tube agglutination test (SAT) titer is 1:100++ and above, or the patient's course of disease lasts for more than one year and still has clinical symptoms, and the titer is 1:50++ and above.
  3. Complement fixation test (CFT) titer is 1:10++ and above.
  4. Anti-human immunoglobulin test (Coomb's) titer is 1:400++ and above.

• Volunteer to join this study.

Exclusion Criteria:

• History of severe lumbar spine trauma before the diagnosis of brucellosis;
• Have undergone lumbosacral surgery before the diagnosis of brucellosis;
• Scoliosis;
• Currently participating in clinical trials of other drugs or medical devices;
• The researchers think it is not suitable for inclusion.

Hospitalized patients diagnosed with Brucellosis from 8 centers in Hubei Province, China.